An investigation that the European Medicines Agency started this month into the risk of suicidal and self-harm thoughts when taking Novo Nordisk’s widely-used drugs for weight loss and type 2 diabetes – Saxenda (liraglutide), Wegovy (semaglutide) and Ozempic (semaglutide) – has been extended to include other GLP-1 receptor agonists.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?